Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma - Summary - MDSpire

Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma

  • By

  • Amit Kumar Mitra

  • Ujjal Kumar Mukherjee

  • Suman Mazumder

  • Vithal Madhira

  • Timothy Bergquist

  • Yu Raymond Shao

  • Feifan Liu

  • Qianqian Song

  • Jing Su

  • Shaji Kumar

  • Benjamin A. Bates

  • Noha Sharafeldin

  • Umit Topaloglu

  • December 7, 2023

  • 0 min

Share

Objective:

To identify predisposing and treatment-related factors associated with COVID-19 severity and mortality in multiple myeloma patients using a large cohort from the National COVID Cohort Collaborative (N3C).

Key Findings:
  • Add context on the implications of findings for treatment strategies.
Interpretation:

Highlight clinical implications more strongly.

Limitations:
  • Include potential confounding factors in the limitations.
Conclusion:

Reiterate the need for further research in the conclusion.

Original Source(s)

Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma

  • by Amit Kumar Mitra, Ujjal Kumar Mukherjee, Suman Mazumder, Vithal Madhira, Timothy Bergquist, Yu Raymond Shao, Feifan Liu, Qianqian Song, Jing Su, Shaji Kumar, Benjamin A. Bates, Noha Sharafeldin, Umit Topaloglu

  • December 7, 2023

Related Content

Case Report: Cytoreductive surgery as a therapeutic attempt in the treatment of extramedullary plasmacytoma

This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet

Lilly moves to acquire Kelonia, plus gene therapy for deafness approved

  • April 27, 2026

  • 6 min
Advancing CAR-T therapy in multiple myeloma: a critical appraisal of CARTITUDE-4 and the path toward earlier lines